首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

市場調查報告書

商品編碼

1776694

2032 年 CRISPR 基因編輯市場預測：按產品類型、技術、應用、最終用戶和地區進行的全球分析

CRISPR Gene Editing Market Forecasts to 2032 - Global Analysis By Product Type, Technology (CRISPR/Cas9, Base Editing, CRISPR/Cpf1, Prime Editing and Other Technologies), Application, End User and By Geography

出版日期: 2025年07月07日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，全球 CRISPR 基因編輯市場預計在 2025 年達到 23 億美元，到 2032 年將達到 128.2 億美元，預測期內的複合年成長率為 27.8%。

CRISPR基因編輯是一種尖端生物技術工具，它使研究人員能夠精確地修改生物體的DNA。受細菌防禦機制的啟發，CRISPR（成簇規律間隔短回文重複序列）使用一種名為Cas9的蛋白質，在可自訂RNA序列的引導下，在特定位點切割DNA。這使得研究人員能夠精確地添加、刪除或替換遺傳物質。此外，CRISPR徹底改變了基因研究，並在生物技術、醫學和農業領域擁有巨大的潛力。 CRISPR為開發新型治療方法、改良作物性狀和治療遺傳疾病提供了令人興奮的可能性。

在歐洲，英國國家醫療服務體系（NHS）核准了Casgevy基因療法用於治療輸血依賴性BETA-地中海貧血，這是歐洲首個由政府支持的CRISPR臨床應用。該治療方法初步估計每位患者費用約為165萬英鎊，將透過NHS惠及最多460名合格的患者，標誌著CRISPR治療方法在歐洲臨床應用方面具有歷史性里程碑。

遺傳疾病的興起

CRISPR 基因編輯市場很大程度上受到全球鐮狀細胞性貧血、BETA-地中海貧血、亨廷頓舞蹈症和囊腫纖維化等遺傳疾病日益流行的推動。這些疾病的傳統治療選擇稀少、昂貴，且往往只針對症狀，而無法解決背後的遺傳原因。 CRISPR 可直接編輯缺陷基因，從而有可能治療方法。隨著人們認知的提高和診斷能力的提高，人們能夠更早發現更多患者，從而推動了對治癒性療法的需求。此外，英國核准，正在推動 CRISPR 從實驗用途走向實際治療用途。

社會和道德問題

圍繞著 CRISPR 基因編輯（尤其是生殖細胞系編輯和人類胚胎的使用）的倫理爭議，是該技術市場發展的最大障礙之一。人們對「設計嬰兒」、意外後果以及人類基因組被改變並可能遺傳給後代對社會產生的長期影響存在嚴重擔憂。宗教、文化和哲學信念進一步加劇了公眾的接受度，尤其是在基因編輯被用於智力或外貌等非治療性增強提案時。此外，人類生殖細胞系編輯仍受到許多監管機構的禁止或嚴格限制。

成為無法治癒的罕見疾病

CRISPR 為治療數千種目前尚無治療方法的罕見遺傳疾病提供了突破性的機會。 CRISPR 有可能在分子層面上糾正導致戴-薩克斯病、Duchenne氏肌肉失養症和萊伯氏先天性黑朦症等疾病的特定基因突變。由於患者人數較少，傳統的罕見疾病藥物研發往往在經濟上難以承受，而 CRISPR 的精準性使其能夠實現有針對性的、可擴展的治療方法。此外，政府和監管機構正在利用孤兒藥資格認定、優先審查和津貼來鼓勵對罕見疾病的研究。

正在進行的知識產權糾紛

CRISPR基因編輯市場正捲入一場曠日持久的專利糾紛，主要機構包括加州大學柏克萊分校和布羅德研究所。由於這些圍繞基本專利的法律糾紛，誰有權使用和銷售CRISPR-Cas9技術的各個部分已成為一個高度不確定的問題。對於尋求開發基於CRISPR產品的公司來說，許可證是一項必要的程序，它複雜、成本高昂，並且因司法管轄區而異。如果沒有明確的營運自由定義，它將阻礙新興企業，扼殺創新，並可能導致法律訴訟。此外，模糊的智慧財產權格局會阻礙合作，增加成本，並嚇跑潛在的投資者。

COVID-19的影響：

COVID-19 疫情對 CRISPR 基因編輯市場產生了雙重影響。一方面，由於供應鏈中斷、臨床試驗延遲以及研究資金重新分配，治療性 CRISPR 應用的進展暫時擱置。實驗室容量減少和關閉也推遲了許多與 COVID-19 無關的基因編輯舉措。然而，疫情也推動了基於 CRISPR 的診斷技術快速發展，SHERLOCK 和 DETECTR 等工具被重新用於快速且準確地檢測 SARS-CoV-2。除了提高公眾認知度和投資者信心之外，這種即時應用還證明了 CRISPR 在基因組編輯之外的適用性。

預計 CRISPR/Cas9 細分市場在預測期內將佔據最大佔有率

由於易用性、高效性和價格實惠，CRISPR/Cas9 細分市場預計將在預測期內佔據最大市場佔有率。 CRISPR/Cas9 是第一個也是最受歡迎的 CRISPR 系統，它徹底改變了基因組編輯。它利用嚮導 RNA 和 Cas9 酶在特定 DNA 位置製造雙鏈，從而實現標靶基因修飾。由於其在學術研究、藥物開發和農業生物技術領域的廣泛應用，CRISPR/Cas9 已成為現代基因編輯的基石。此外，CRISPR/Cas9 目前已在許多臨床試驗中用於治療感染疾病、癌症和遺傳疾病，進一步鞏固了其在全球 CRISPR 市場的主導地位。

預計製藥和生物製藥領域在預測期內將以最高的複合年成長率成長

預計製藥和生物製藥公司細分市場將在預測期內實現最高成長率。基因療法開發投資的不斷增加、個人化醫療的需求以及基於 CRISPR 的藥物研發管線的加速發展是這項擴張的關鍵驅動力。為了開發感染疾病、罕見遺傳疾病和癌症的治療方法，這些公司正在積極採用 CRISPR 技術。與生物技術公司和 CRISPR 先驅的合作正在加速臨床試驗和監管核准。此外，隨著 Casjevy 等 CRISPR 療法核准，製藥公司正在加強生產和商業化力度，確保該市場作為成長最快的基因編輯市場佔據主導地位。

比最大的地區

預計北美將在預測期內佔據最大的市場佔有率，這主要得益於其率先採用尖端基因編輯技術、強大的生物技術基礎設施以及充足的研究資金。美國處於領先地位，其關鍵產業相關人員和學術機構高度集中，監管支持有力，並進行了大量的CRISPR相關臨床試驗。在生技公司積極推動治療方案開發的同時，美國國立衛生研究院（NIH）等政府機構也大力投資基因組編輯研究。該地區還受益於強大的智慧財產權框架和高度的公私合作。

複合年成長率最高的地區：

預計亞太地區將在預測期內呈現最高的複合年成長率，這得益於政府支持、精準醫療投資以及生物技術研究的成長。中國、日本、韓國和印度等國家正在基因組學領域取得快速發展，基於 CRISPR 的研究計劃和臨床研究不斷增加。旨在促進生物技術創新的資助計劃和監管變化進一步推動了市場擴張。此外，由於人口眾多、遺傳疾病發病率不斷上升以及國際製藥公司對本地合作的興趣日益濃厚，亞太地區正成為 CRISPR 技術應用的主要新興中心。

免費客製化服務：

此報告的訂閱者可以從以下免費自訂選項中選擇一項：

公司簡介
- 對最多三家其他市場公司進行全面分析
- 主要企業的SWOT分析（最多3家公司）
區域細分
- 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
競爭基準化分析
- 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 其他歐洲國家
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 紐西蘭
- 韓國
- 其他亞太地區
南美洲
- 阿根廷
- 巴西
- 智利
- 南美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 南非
- 其他中東和非洲地區

第10章：主要發展

協議、夥伴關係、合作和合資企業
收購與合併
新產品發布
業務擴展
其他關鍵策略

第11章公司概況

Danaher
Thermo Fisher Scientific, Inc.
Merck KGaA
Bio-Rad Laboratories Inc
GenScript Inc
Agilent Technologies, Inc.
New England Biolabs, Inc.
CRISPR Therapeutics AG
OriGene Technologies, Inc.
Synthego Corporation
Cellecta, Inc.
Rockland Immunochemicals, Inc.
Integrated DNA Technologies, Inc.
Beam Therapeutics Inc
Locus Biosciences Inc

簡介目錄圖表

Product Code: SMRC30025

According to Stratistics MRC, the Global CRISPR Gene Editing Market is accounted for $2.30 billion in 2025 and is expected to reach $12.82 billion by 2032 growing at a CAGR of 27.8% during the forecast period. CRISPR gene editing is a cutting-edge biotechnology tool that enables researchers to precisely modify living things' DNA. Drawing inspiration from a bacterial defense mechanism, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) employs a protein called Cas9 to cut DNA at specific sites under the guidance of an RNA sequence that can be customized. This gives researchers the ability to precisely add, remove, or replace genetic material. Moreover, CRISPR has revolutionized genetic research and has enormous potential in biotechnology, medicine, and agriculture. It presents exciting opportunities for the development of novel treatments, the improvement of crop traits, and the treatment of genetic disorders.

According to the first government-backed clinical application of CRISPR in Europe, NHS England has approved the use of the gene therapy Casgevy for transfusion-dependent beta-thalassemia. The treatment-initially listed at approximately £1.65 million per patient-is being offered through the NHS to up to 460 eligible patients, marking a historic milestone in the clinical adoption of CRISPR-based therapies across Europe.

Market Dynamics:

Driver:

Growing incidence of genetic conditions

The CRISPR gene editing market is being driven largely by the increasing prevalence of genetic diseases like sickle cell anemia, beta-thalassemia, Huntington's disease, and cystic fibrosis worldwide. In contrast to addressing the underlying genetic causes, traditional treatment options for these conditions are frequently scarce, costly, and symptom-focused. CRISPR directly edits faulty genes, potentially providing a remedy. The need for curative therapies is being fueled by the increased early identification of more patients due to increased awareness and improved diagnostic capabilities. Additionally, with regulatory approvals such as the UK NHS's and FDA's approval of Casgevy, CRISPR is progressing from the experimental stage to practical therapeutic use.

Restraint:

Social and ethical issues

The ethical controversy surrounding the use of CRISPR gene editing, especially in germline editing and human embryos, is one of the biggest obstacles to the market. There are serious worries about "designer babies," unforeseen consequences, and the long-term effects on society when the human genome is altered in ways that can be passed on to future generations. Public acceptance is further complicated by religious, cultural, and philosophical beliefs, particularly when editing is suggested for non-therapeutic enhancements like intelligence or appearance. Furthermore, human germline editing is still prohibited or severely restricted by numerous regulatory bodies.

Opportunity:

Growth into untreatable and rare illnesses

CRISPR presents a game-changing chance to treat thousands of uncommon genetic illnesses for which there is currently no cure. CRISPR may be able to fix certain gene mutations that cause diseases like Tay-Sachs, Duchenne muscular dystrophy, and Leber congenital amaurosis at the molecular level. Small patient populations often make traditional drug development for rare diseases financially unfeasible, but CRISPR's accuracy enables targeted, scalable therapeutic approaches. Additionally, orphan drug designations, priority reviews, and grant funding are being used by governments and regulatory bodies to encourage research into rare diseases.

Threat:

Continuous intellectual property (IP) conflicts

The market for CRISPR gene editing is enmeshed in protracted patent disputes between leading organizations, including the University of California, Berkeley, and the Broad Institute. Who has the authority to use and market different parts of the CRISPR-Cas9 technology is a matter of considerable uncertainty as a result of these legal disputes over the fundamental patents. Licenses are necessary for businesses wishing to create CRISPR-based products, and they can be complicated, costly, and jurisdiction-specific. Without a clear definition of freedom to operate, this could discourage startups, impede innovation, or lead to legal action. Additionally, the ambiguous IP landscape hinders cooperation, raises expenses, and deters potential investors.

Covid-19 Impact:

The COVID-19 pandemic affected the market for CRISPR gene editing in two ways: it brought opportunities and challenges. On the one hand, advancements in therapeutic CRISPR applications were momentarily put on hold due to supply chain disruptions, clinical trial delays, and reallocated research funds. Due to lab capacity reductions and lockdowns, numerous gene-editing initiatives unrelated to COVID-19 experienced delays. However, CRISPR-based diagnostics have advanced rapidly as a result of the pandemic, with tools like SHERLOCK and DETECTR being repurposed for the quick and precise detection of SARS-CoV-2. In addition to increasing public awareness and investor confidence, this real-time application demonstrated CRISPR's adaptability beyond genome editing.

The CRISPR/Cas9 segment is expected to be the largest during the forecast period

The CRISPR/Cas9 segment is expected to account for the largest market share during the forecast period because of its ease of use, effectiveness, and affordability, CRISPR/Cas9, the first and most popular CRISPR system, has completely changed genome editing. It enables targeted gene modifications by causing double-strand breaks at particular DNA locations using a guide RNA and the Cas9 enzyme. It is the cornerstone of contemporary gene editing due to its widespread application in scholarly research, pharmaceutical development, and agricultural biotechnology. Moreover, CRISPR/Cas9 is currently being used in a large number of clinical trials to treat infectious diseases, cancer, and genetic disorders, further solidifying its leading position in the global CRISPR market.

The pharmaceutical and biopharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical and biopharmaceutical companies segment is predicted to witness the highest growth rate. Growing investments in the development of gene therapies, the need for personalized medicine, and the quickening of CRISPR-based drug pipelines are the main drivers of this expansion. To create treatments for infectious diseases, rare genetic diseases, and cancer, these businesses are aggressively incorporating CRISPR technologies. Partnerships with biotech companies and CRISPR pioneers have accelerated clinical trials and regulatory approvals. Additionally, pharmaceutical companies are increasing production and commercialization of CRISPR therapies, such as Casgevy, as they receive approval, securing this market's dominance as the fastest-growing gene editing market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, mainly because of its early adoption of cutting-edge gene-editing technologies, strong biotechnology infrastructure, and generous research funding. With a concentration of important industry players and academic institutions, favorable regulatory support, and extensive clinical trials related to CRISPR, the United States leads the way. While biotech companies actively seek therapeutic development, government organizations such as the NIH make significant investments in genome-editing research. Furthermore, the area also gains from a robust intellectual property framework and a high degree of public-private cooperation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by growing government assistance, precision medicine investments, and biotechnology research. With an increasing number of CRISPR-based research projects and clinical studies, nations like China, Japan, South Korea, and India are making rapid strides in genomics. Market expansion is further supported by funding initiatives and regulatory changes meant to promote biotech innovation. Moreover, Asia-Pacific is positioned as a major emerging hub for the adoption of CRISPR technology due to its large population base, rising prevalence of genetic disorders, and growing interest from international pharmaceutical companies in local partnerships.

Key players in the market

Some of the key players in CRISPR Gene Editing Market include Danaher, Thermo Fisher Scientific, Inc., Merck KGaA, Bio-Rad Laboratories Inc, GenScript Inc, Agilent Technologies, Inc., New England Biolabs, Inc., CRISPR Therapeutics AG, OriGene Technologies, Inc., Synthego Corporation, Cellecta, Inc., Rockland Immunochemicals, Inc., Integrated DNA Technologies, Inc., Beam Therapeutics Inc and Locus Biosciences Inc.

Key Developments:

In June 2025, Thermo Fisher Scientific announced that it has been awarded a five-year, $94.5 million contract by the U.S. Department of Defense (DoD) to supply the Navy with a next-generation dosimetry system alongside updated radiation health and database management software. The U.S. Navy operates the world's most technologically advanced naval fleet and is the largest defense user of dosimetry systems globally.

In April 2025, Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics, for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents. The deal came at a price tag about 20% lower than what analysts expected due to lack of other serious bidders and the overall devaluation of the U.S. biotech sector. CEO Belen Garijo said the challenges emerging in the United States were reflected in the final bid price.

In January 2025, Danaher Corporation announced that it has signed a definitive agreement to sell its Pacific Scientific Aerospace business to Meggitt PLC, a global aerospace and defense company. Danaher simultaneously received a binding offer from Meggitt to acquire the Artus business which remains open for 12 months. As required by French law, Danaher must consult with the Artus works council prior to concluding an agreement for the sale of the Artus business.

Product Types Covered:

CRISPR Kits & Reagent
CRISPR Services

Technologies Covered:

CRISPR/Cas9
Base Editing
CRISPR/Cpf1 (Cas12a)
Prime Editing
Other Technologies

Applications Covered:

Agricultural
Biomedical
Industrial Biotechnology
Other Applications

End Users Covered:

Academic Institutes and Research Centres
Biotechnology Companies
Contract Research Organizations (CROs)
Pharmaceutical and Biopharmaceutical Companies
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 End User Analysis
3.10 Emerging Markets
3.11 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global CRISPR Gene Editing Market, By Product Type

5.1 Introduction
5.2 CRISPR Kits & Reagent
- 5.2.1 Kits and Enzymes
- 5.2.2 Libraries
- 5.2.3 Design Tools
- 5.2.4 Antibodies
- 5.2.5 Other CRISPR Kits & Reagents
5.3 CRISPR Services
- 5.3.1 gRNA Design and Vector Construction
- 5.3.2 Cell Line Engineering
- 5.3.3 Screening Services
- 5.3.4 Other CRISPR Services

6 Global CRISPR Gene Editing Market, By Technology

6.1 Introduction
6.2 CRISPR/Cas9
6.3 Base Editing
6.4 CRISPR/Cpf1 (Cas12a)
6.5 Prime Editing
6.6 Other Technologies

7 Global CRISPR Gene Editing Market, By Application

7.1 Introduction
7.2 Agricultural
- 7.2.1 Crop Trait Improvement
- 7.2.2 Livestock Genome Editing
- 7.2.3 Pathogen Resistance
7.3 Biomedical
- 7.3.1 Therapeutic Genome Editing
- 7.3.2 Disease Models
- 7.3.3 Functional Genomics
- 7.3.4 Gene Therapy Research
7.4 Industrial Biotechnology
- 7.4.1 Microbial Strain Engineering
- 7.4.2 Biofuel Production
- 7.4.3 Enzyme Optimization
7.5 Other Applications

8 Global CRISPR Gene Editing Market, By End User

8.1 Introduction
8.2 Academic Institutes and Research Centres
8.3 Biotechnology Companies
8.4 Contract Research Organizations (CROs)
8.5 Pharmaceutical and Biopharmaceutical Companies
8.6 Other End Users

9 Global CRISPR Gene Editing Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Danaher
11.2 Thermo Fisher Scientific, Inc.
11.3 Merck KGaA
11.4 Bio-Rad Laboratories Inc
11.5 GenScript Inc
11.6 Agilent Technologies, Inc.
11.7 New England Biolabs, Inc.
11.8 CRISPR Therapeutics AG
11.9 OriGene Technologies, Inc.
11.10 Synthego Corporation
11.11 Cellecta, Inc.
11.12 Rockland Immunochemicals, Inc.
11.13 Integrated DNA Technologies, Inc.
11.14 Beam Therapeutics Inc
11.15 Locus Biosciences Inc

簡介目錄圖表

List of Tables

Table 1 Global CRISPR Gene Editing Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global CRISPR Gene Editing Market Outlook, By Product Type (2024-2032) ($MN)
Table 3 Global CRISPR Gene Editing Market Outlook, By CRISPR Kits & Reagent (2024-2032) ($MN)
Table 4 Global CRISPR Gene Editing Market Outlook, By Kits and Enzymes (2024-2032) ($MN)
Table 5 Global CRISPR Gene Editing Market Outlook, By Libraries (2024-2032) ($MN)
Table 6 Global CRISPR Gene Editing Market Outlook, By Design Tools (2024-2032) ($MN)
Table 7 Global CRISPR Gene Editing Market Outlook, By Antibodies (2024-2032) ($MN)
Table 8 Global CRISPR Gene Editing Market Outlook, By Other CRISPR Kits & Reagents (2024-2032) ($MN)
Table 9 Global CRISPR Gene Editing Market Outlook, By CRISPR Services (2024-2032) ($MN)
Table 10 Global CRISPR Gene Editing Market Outlook, By gRNA Design and Vector Construction (2024-2032) ($MN)
Table 11 Global CRISPR Gene Editing Market Outlook, By Cell Line Engineering (2024-2032) ($MN)
Table 12 Global CRISPR Gene Editing Market Outlook, By Screening Services (2024-2032) ($MN)
Table 13 Global CRISPR Gene Editing Market Outlook, By Other CRISPR Services (2024-2032) ($MN)
Table 14 Global CRISPR Gene Editing Market Outlook, By Technology (2024-2032) ($MN)
Table 15 Global CRISPR Gene Editing Market Outlook, By CRISPR/Cas9 (2024-2032) ($MN)
Table 16 Global CRISPR Gene Editing Market Outlook, By Base Editing (2024-2032) ($MN)
Table 17 Global CRISPR Gene Editing Market Outlook, By CRISPR/Cpf1 (Cas12a) (2024-2032) ($MN)
Table 18 Global CRISPR Gene Editing Market Outlook, By Prime Editing (2024-2032) ($MN)
Table 19 Global CRISPR Gene Editing Market Outlook, By Other Technologies (2024-2032) ($MN)
Table 20 Global CRISPR Gene Editing Market Outlook, By Application (2024-2032) ($MN)
Table 21 Global CRISPR Gene Editing Market Outlook, By Agricultural (2024-2032) ($MN)
Table 22 Global CRISPR Gene Editing Market Outlook, By Crop Trait Improvement (2024-2032) ($MN)
Table 23 Global CRISPR Gene Editing Market Outlook, By Livestock Genome Editing (2024-2032) ($MN)
Table 24 Global CRISPR Gene Editing Market Outlook, By Pathogen Resistance (2024-2032) ($MN)
Table 25 Global CRISPR Gene Editing Market Outlook, By Biomedical (2024-2032) ($MN)
Table 26 Global CRISPR Gene Editing Market Outlook, By Therapeutic Genome Editing (2024-2032) ($MN)
Table 27 Global CRISPR Gene Editing Market Outlook, By Disease Models (2024-2032) ($MN)
Table 28 Global CRISPR Gene Editing Market Outlook, By Functional Genomics (2024-2032) ($MN)
Table 29 Global CRISPR Gene Editing Market Outlook, By Gene Therapy Research (2024-2032) ($MN)
Table 30 Global CRISPR Gene Editing Market Outlook, By Industrial Biotechnology (2024-2032) ($MN)
Table 31 Global CRISPR Gene Editing Market Outlook, By Microbial Strain Engineering (2024-2032) ($MN)
Table 32 Global CRISPR Gene Editing Market Outlook, By Biofuel Production (2024-2032) ($MN)
Table 33 Global CRISPR Gene Editing Market Outlook, By Enzyme Optimization (2024-2032) ($MN)
Table 34 Global CRISPR Gene Editing Market Outlook, By Other Applications (2024-2032) ($MN)
Table 35 Global CRISPR Gene Editing Market Outlook, By End User (2024-2032) ($MN)
Table 36 Global CRISPR Gene Editing Market Outlook, By Academic Institutes and Research Centres (2024-2032) ($MN)
Table 37 Global CRISPR Gene Editing Market Outlook, By Biotechnology Companies (2024-2032) ($MN)
Table 38 Global CRISPR Gene Editing Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
Table 39 Global CRISPR Gene Editing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2024-2032) ($MN)
Table 40 Global CRISPR Gene Editing Market Outlook, By Other End Users (2024-2032) ($MN)